Doctor Anywhere, a Singapore-based telemedicine startup, raises $27M Series B, says it will use the funds to expand into Malaysia and the Philippines
Olivia Poh / The Business Times :
Context & Ripple Effects
Doctor Anywhere's $27M Series B lands at the start of a regional telemedicine funding wave — the same month London-based Air Doctor raised $7.8M for traveler-focused consultations across 42 countries, and weeks before China's Miaoshou Doctor pulled in roughly $84M at Series D. The Singapore startup is betting the money on geographic expansion rather than product depth, pushing into Malaysia and the Philippines.
The bet aged well by the corpus's own record: sixteen months later Doctor Anywhere closed a ~$65.3M Series C led by Asia Partners, lifting its total raised to $140M — while Indonesia's Halodoc raised an $80M Series C of its own, confirming that multi-country Southeast Asian teleconsultation had become a scale game.
First-order effects
- Doctor Anywhere immediately gains the capital to stand up operations in Malaysia and the Philippines, moving from a single-market Singapore service to a three-country footprint.
Second-order effects
- Regional rivals respond in kind: Halodoc's subsequent $80M Series C shows competing teleconsult-and-drug-delivery platforms raising larger rounds to defend their own national markets, pushing the contest toward who can cover more countries faster.
Third-order effects
- If the pattern holds, Southeast Asian telemedicine consolidates around a handful of well-capitalized multi-country platforms — Doctor Anywhere's path from $27M to $140M total suggests late-stage capital concentrates on the expanders, squeezing out single-market operators.
The trend: Southeast Asian telemedicine is scaling from single-country services into region-wide platforms, with each successive funding round financing entry into new national markets.